10 November 2023
Current Oncology | World Neuroendocrine Tumor Awareness Day (NET Cancer Day) 2023

World Neuroendocrine Tumor Awareness Day (NET Cancer Day) takes place annually on the 10 November and it is coordinated by the International Neuroendocrine Cancer Alliance (INCA). The main objectives of this event are to increase awareness about various types of neuroendocrine tumors (NETs), advocate for scientific progress by addressing unmet needs, and foster global collaboration to tackle the challenges faced by NET patients and the medical community in terms of timely diagnosis, optimal treatment, and support.

In celebration of NET Cancer Day 2023, Current Oncology (ISSN: 1718-7729) has curated a collection of open access scholarly research studies focused on neuroendocrine tumors. Our intention is to disseminate new scientific knowledge to the world on this significant occasion.

1. “Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study”
by Golmehr Sistani, Duncan E. K. Sutherland, Amol Mujoomdar, Daniele P. Wiseman, Alireza Khatami, Elena Tsvetkova, Robert H. Reid and David T. Laidley
Curr. Oncol. 2021, 28(1), 115–127;
Available online: 

2. “Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors”
by Taymeyah Al-Toubah, Brian Morse and Jonathan Strosberg
Curr. Oncol. 2022, 29(2), 510–515;
Available online:

3. “Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden”
by Nai-Wen Kang, Kien-Thiam Tan, Chien-Feng Li and Yu-Hsuan Kuo
Curr. Oncol. 2021, 28(6), 4587–4596;
Available online:

4. “A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib”
by Chloe A. Lim, Norbert Banyi, Tracy Tucker, Diana N. Ionescu and Barbara Melosky
Curr. Oncol. 2022, 29(2), 848–852;
Available online:

5. “Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms—A Single-Center Retrospective Outcome Analysis”
by Kirsten Lindner, Daniel Binte, Jens Hoeppner, Ulrich F. Wellner, Dominik M. Schulte, Sebastian M. Schmid, Kim Luley, Inga Buchmann, Lars Tharun, Tobias Keck et al.
Curr. Oncol. 2021, 28(4), 3071–3080;
Available online:

6. “Neuroendocrine Carcinomas of the Uterine Cervix, Endometrium, and Ovary Show Higher Tendencies for Bone, Brain, and Liver Organotrophic Metastases”
by Hyung Kyu Park
Curr. Oncol. 2022, 29(10), 7461–7469;
Available online:

7. “Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER”
by Zefeng Li, Hu Ren, Lulu Zhao, Xiaojie Zhang, Tongbo Wang, Chongyuan Sun, Penghui Niu, Wanqing Wang, He Fei, Chunguang Guo et al.
Curr. Oncol. 2022, 29(7), 4879–4892;
Available online:

8. “The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases”
by Zainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, Xin Wang, Melissa Frizziero, Bipasha Chakrabarty, Prakash Manoharan, Catherine McBain, Was Mansoor, Angela Lamarca et al.
Curr. Oncol. 2022, 29(7), 5110–5125;
Available online:

9. “Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors”
by Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti and Davide Campana
Curr. Oncol. 2023, 30(2), 1381–1394;
Available online:

10. “Comparison of Transarterial Bland and Chemoembolization for Neuroendocrine Tumours: A Systematic Review and Meta-Analysis”
by E. Tai, S. Kennedy, A. Farrell, A. Jaberi, J. Kachura and R. Beecroft
Curr. Oncol. 2020, 27(6), 537–546;
Available online:

More News...
Back to TopTop